Full Title
A Phase Ib/II study of pembrolizumab, ibrutinib and rituximab in refractory/relapsed primary central nervous system lymphoma (PCNSL)Purpose
Researchers want to see if combining pembrolizumab, ibrutinib, and rituximab works well against primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that keeps growing or came back even with treatment.
Pembrolizumab is an immunotherapy. It boosts the power of your immune system to find and kill cancer cells. Rituximab binds to the CD20 protein on cancer cells. This binding action helps the immune system to kill cancer cells. Pembrolizumab and rituximab are both given intravenously (by vein).
Ibrutinib inhibits BTK, a protein that drives cancer growth. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have PCNSL that keeps growing or came back after treatment.
- Have recovered from the serious side effects of prior therapies before getting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Christian Grommes’ office at 212-610-0344.